Skip to Content
Søk Menu

High lights from ASCO about prostate and kidney cancer

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relateret indhold

Maria Teresa Bourlon

Nivolumab + Cabozantinib Remains Standard of Care in First-Line Treatment for Advanced Renal Cell Carcinoma

/ Maria Teresa Bourlon
Nyrekreft Play the Video 5:36
Marc Eid og Karl Semaan

Cancer Epigenomics Improve the Overall Survival and the Quality of Life

/ Marc Eid / Karl Semaan
ASCOGU24Prostatakreft Play the Video 1:31
Wadih Issa

Comparing Downstaging in RCC-Patients with Tumor or Without Tumor Thrombus Receiving Neoadjuvant ICI Regimen

/ Wadih Issa
ASCOGU24Nyrekreft Play the Video 1:47
Marc Machaalani

Host Immune Signatures as Predictors for Immunotherapy Regimens in Patients with Metastatic Renal Cell Carcinoma

/ Marc Machaalani
Nyrekreft Play the Video 2:11
Eddy Saad

Understanding Mechanisms Behind Acquired Resistance to Immunotherapy in Metastatic Renal Cell Carcinoma

/ Eddy Saad
ASCOGU24Nyrekreft Play the Video 2:21
Renee Maria Saliby

The Potential for Intermediate Clinical Endpoints as Surrogates for Overall Survival

/ Renee Maria Saliby
ASCOGU24Nyrekreft Play the Video 2:46
Philipp Ivanyi

Real-World Evidence on Lenvatinib plus Everolimus in Patients with Pre-Treated Advanced Renal Cell Carcinoma

/ Philipp Ivanyi
ASCOGU24Nyrekreft Play the Video 3:16

ASCO GU 2024: CheckMate 914 Trial – Adjuvant Nivolumab Monotherapy vs Placebo for Localized Renal Cell Carcinoma at High Risk of Relapse After Nephrectomy

/ Sofie Pohl
ASCOGU24Nyrekreft
Thomas Powles

Patient-Reported Outcomes of Belzutifan versus Everolimus in Patients with Previously Treated Advanced Renal Cell Carcinoma

/ Thomas Powles
ASCOGU24Nyrekreft Play the Video 01:59
Back to top